The Alvarez Law Firm
(305) 444-7675 Free Case Review
FDA Actions & Safety Alerts

FDA Warnings, Recalls &
Import Alerts

The FDA has taken multiple enforcement actions against Olympus endoscopes over the past decade, including safety communications, postmarket surveillance orders, Class I recalls — the most serious recall classification — and an unprecedented import alert covering 58 Olympus endoscope models. These actions confirm what patients and hospitals were not told: these devices posed known, serious contamination risks.

If you or a loved one developed an infection after an endoscopic procedure, the FDA's own findings may support your legal claim. Our team — including a medical-legal expert with both an M.D. and J.D. — is ready to review your case at no cost.

Free Endoscope Case Review (305) 444-7675
Scroll
A Decade of Regulatory Action

Timeline of FDA Actions Against Olympus

The FDA has been aware of contamination risks with Olympus endoscopes for more than a decade. Despite repeated warnings, safety communications, and regulatory actions, these dangerous devices continued to be used on millions of patients. Here is the full timeline of the FDA's response to the Olympus endoscope contamination crisis.

1
2015

FDA Safety Communication on Duodenoscope Design

The FDA issued a critical safety communication alerting healthcare providers and patients about serious concerns with duodenoscope design and the challenges of reprocessing these complex devices. The communication came after multiple hospital outbreaks of antibiotic-resistant infections were traced to contaminated Olympus TJF-Q180V duodenoscopes.

Investigations at hospitals including Virginia Mason Medical Center in Seattle, Ronald Reagan UCLA Medical Center, and Cedars-Sinai Medical Center in Los Angeles revealed that patients were contracting carbapenem-resistant Enterobacteriaceae (CRE) — a class of antibiotic-resistant superbugs with mortality rates as high as 50% — from contaminated Olympus duodenoscopes. Despite hospitals following Olympus's own recommended cleaning protocols, the scopes remained contaminated and continued to transmit deadly infections between patients. The FDA acknowledged that the design of these devices made complete disinfection extremely difficult, if not impossible.

2
2016

FDA Orders Postmarket Surveillance Studies

Recognizing the severity of the contamination problem, the FDA took the unprecedented step of ordering duodenoscope manufacturers — including Olympus — to conduct postmarket surveillance studies to determine the real-world contamination rates of their devices. This was a significant regulatory action that went beyond the typical safety communication. The FDA mandated that manufacturers actively study how often their devices remained contaminated after hospitals followed recommended reprocessing procedures.

The results of these studies were alarming. Sampling and culturing of reprocessed duodenoscopes revealed contamination rates far higher than what manufacturers had previously disclosed. Even when healthcare facilities adhered to every step of the manufacturer-recommended cleaning and disinfection protocols, bacterial contamination persisted in the internal channels and elevator mechanisms of the scopes. These findings confirmed what infection control experts had feared: the design of Olympus duodenoscopes made them inherently impossible to reliably disinfect between patients.

3
2019

FDA Recommends Transition to Disposable Scopes

After years of mounting evidence that reusable duodenoscopes could not be adequately disinfected, the FDA issued an updated safety communication recommending that healthcare facilities transition to disposable or semi-disposable duodenoscopes. This recommendation was a tacit admission that the fundamental design of reusable Olympus duodenoscopes was flawed and could not be made safe through improved cleaning protocols alone.

The FDA's recommendation acknowledged that innovative disposable components — particularly disposable elevator caps and disposable endcaps — could reduce the risk of cross-contamination between patients. However, many hospitals continued using their existing inventory of reusable Olympus scopes due to the high cost of replacement equipment and the logistical challenges of transitioning to new devices. Patients undergoing procedures at these facilities were not informed that the FDA had recommended alternatives to the very devices being used on them, nor were they told about the contamination risks associated with reusable scopes.

4
January 2025

Class I Recall: Forceps/Irrigation Plug (MAJ-891)

Olympus issued a voluntary advisory notice and the FDA classified it as a Class I recall — the most serious type of recall — for the Forceps/Irrigation Plug (MAJ-891). This component is used with multiple Olympus endoscope models and was recalled due to contamination risk. The Class I classification means the FDA determined there was a reasonable probability that use of the product would cause serious adverse health consequences or death.

The recall specifically addressed concerns that the MAJ-891 plug could allow biological material to accumulate and transmit between patients, even after reprocessing. This was not a minor technical issue — the Class I designation is reserved for situations where the FDA believes the device poses the most serious possible threat to patient safety. The recall affected plugs distributed to hospitals and healthcare facilities across the United States, raising questions about how many patients may have been exposed to contaminated devices before the recall was initiated.

5
June 2025

FDA Import Alert: 58 Olympus Endoscope Models Blocked

In the most significant regulatory action against Olympus to date, the FDA issued an import alert covering 58 models of Olympus endoscope devices manufactured at Olympus facilities in Japan. The FDA cited concerns about manufacturing practices and regulatory compliance, effectively authorizing U.S. Customs and Border Protection to detain these devices at the border without physical examination.

An import alert of this magnitude against a major medical device manufacturer is exceptionally rare. It signals that the FDA had identified systemic problems with how Olympus manufactured these devices — problems significant enough to warrant blocking an entire category of products from entering the country. The 58 models covered by the alert included endoscopes used across virtually every type of endoscopic procedure: colonoscopies, ERCP, gastroscopies, bronchoscopies, and more. This action sent a clear message that the FDA considered these devices to be unsafe for use on patients.

Understanding FDA Recalls

What Is a Class I Recall?

The FDA classifies medical device recalls into three categories based on the severity of the health risk. Olympus endoscope components have received a Class I recall — the highest and most dangerous classification the FDA assigns. Understanding these classifications is critical to grasping the severity of the risks posed by contaminated Olympus scopes.

Most Serious

Class I Recall

A Class I recall is the most serious type of recall. It indicates that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. These recalls address situations where the device defect poses an immediate and substantial danger to patients.

Class I recalls are relatively rare and are reserved for the most dangerous situations. When the FDA classifies a recall as Class I, it is sending a clear signal that the device in question poses a threat to human life. The Olympus Forceps/Irrigation Plug (MAJ-891) received a Class I recall in January 2025 — confirming that the FDA determined this component posed a risk of serious injury or death due to contamination.

Olympus endoscope components have received this classification.

Class II Recall

A Class II recall addresses situations where use of the product may cause temporary or medically reversible adverse health consequences. While serious, the probability of severe health consequences is considered remote compared to Class I. Most medical device recalls fall into this category.

Class II recalls typically involve devices that may malfunction or underperform but are less likely to result in death or permanent injury. They still require prompt action by healthcare facilities, but the risk level is a step below the immediate life-threatening danger associated with Class I.

Class III Recall

A Class III recall involves a situation where the use of the product is not likely to cause adverse health consequences. These recalls are the least serious and often address labeling errors, minor manufacturing deviations, or other issues that do not directly threaten patient safety.

Class III recalls are the most common and least concerning category. They typically involve administrative or regulatory issues rather than direct patient harm. The fact that Olympus's recall was classified at the opposite end of this spectrum — Class I, the most severe — underscores the gravity of the contamination risks identified by the FDA.

The distinction between recall classes matters significantly in legal cases. A Class I recall demonstrates that the FDA itself determined that the device posed a risk of serious injury or death. This finding by a federal regulatory agency is powerful evidence that the device was defective and unreasonably dangerous, which are key elements in product liability and medical device lawsuits. Olympus endoscope components have received the most serious classification the FDA can assign.

June 2025 Import Alert

The FDA Import Alert: 58 Models Blocked

In June 2025, the FDA took one of its most significant regulatory actions against a major medical device manufacturer, issuing an import alert that effectively blocked 58 Olympus endoscope models from entering the United States. This section explains what import alerts are, why this action was so unusual, and what it means for patients who were exposed to these devices.

What Is an FDA Import Alert?

An import alert is a regulatory mechanism that allows the FDA to detain products at the U.S. border without conducting a physical examination. When the FDA issues an import alert against a product or manufacturer, it means that U.S. Customs and Border Protection is authorized to automatically hold shipments of those products, preventing them from entering the country and reaching hospitals and patients. Import alerts are typically issued when the FDA has evidence that products violate U.S. laws or regulations and pose a risk to public health.

Why This Import Alert Was Extraordinary

Import alerts against major medical device manufacturers are exceedingly rare. Olympus is one of the largest endoscope manufacturers in the world, supplying devices to hospitals and surgical centers across the globe. For the FDA to block 58 separate models of Olympus endoscopes represents a sweeping regulatory action that signals deep, systemic concerns about the safety and compliance of these devices. This was not a targeted action against a single product or a single manufacturing lot — it was a broad enforcement action spanning dozens of device models manufactured at Olympus facilities in Japan.

What the FDA Cited

The FDA cited concerns about manufacturing practices and regulatory compliance at Olympus's Japanese manufacturing facilities. While the specific details of the FDA's findings involve confidential inspection records, the scope of the import alert — covering 58 distinct device models — suggests that the problems were not isolated to a single production line or a single type of endoscope. Instead, the alert pointed to broader issues with how Olympus manufactured, tested, and ensured the safety of its endoscope product line.

  • 58 endoscope models were covered by the import alert, spanning multiple categories of endoscopic devices used in a wide range of medical procedures

  • Manufactured in Japan at Olympus facilities that supply endoscopes to healthcare providers around the world

  • Detention without examination — the import alert authorized automatic detention at the border, meaning the FDA considered the risk serious enough to block these devices preemptively

  • Rarely used against major manufacturers — import alerts of this scale are uncommon and reflect the FDA's judgment that the products posed a significant public health concern

58

Endoscope Models Blocked

The import alert covered 58 distinct Olympus endoscope models, representing a sweeping regulatory action against one of the world's largest medical device manufacturers

June 2025

Date of Import Alert

The import alert was issued in June 2025, following a decade of safety communications, recalls, and growing evidence of contamination risks

Impact on Hospitals

The import alert did not retroactively remove Olympus endoscopes already in use at U.S. hospitals. Many healthcare facilities may still have Olympus scopes in their inventory that were manufactured before the import alert took effect. This means patients may continue to be exposed to devices that the FDA has flagged for manufacturing and compliance concerns. Hospitals have a responsibility to evaluate their existing Olympus endoscope inventory in light of the FDA's findings and take appropriate action to protect their patients.

Legal Significance

The import alert is significant evidence in lawsuits against Olympus. It demonstrates that the FDA identified systemic manufacturing and compliance problems serious enough to warrant blocking an entire product line. In product liability litigation, regulatory actions by federal agencies carry substantial weight because they represent independent government findings about the safety of a product. Patients who developed infections from Olympus endoscopes can point to this import alert as evidence that the devices were defective and that Olympus failed to maintain adequate manufacturing standards.

Your Rights & Next Steps

What This Means for Patients

If you had a procedure with an Olympus endoscope, the FDA's regulatory actions carry direct implications for your health, your rights, and your ability to seek justice. These are not theoretical concerns — they are documented federal findings about devices that may have been used on you or your loved ones.

FDA Actions Confirm Known Risks

If you had a procedure with an Olympus endoscope, the FDA's repeated safety communications, recalls, and import alerts confirm that these devices posed known contamination risks. The FDA does not take these actions lightly. Each regulatory step represents a formal finding that the devices failed to meet safety standards. The progression from safety communications in 2015 to a Class I recall and a 58-model import alert in 2025 demonstrates that the risks were not only known but escalating. The government's own regulatory record establishes that Olympus endoscopes were defective and dangerous.

Hospitals May Not Have Told You

Many patients who underwent endoscopic procedures were never informed about the contamination risks associated with Olympus scopes. Hospitals and healthcare facilities had access to FDA safety communications, recall notices, and postmarket surveillance data, but many did not pass this information along to patients. You may have undergone a colonoscopy, ERCP, bronchoscopy, or other endoscopic procedure without knowing that the device being used on you had been the subject of federal safety concerns. In some cases, hospitals continued using Olympus scopes even after the FDA recommended transitioning to disposable alternatives, without informing patients of the additional risk.

FDA Actions Strengthen Legal Claims

In product liability and medical device litigation, regulatory actions by federal agencies are powerful evidence. The FDA's safety communications, recall classifications, postmarket surveillance orders, and import alerts establish an official government record that Olympus endoscopes were known to be defective. These findings help satisfy key legal elements in contaminated endoscope lawsuits, including establishing that the devices were unreasonably dangerous, that Olympus knew or should have known about the risks, and that the company failed to take adequate steps to protect patients. The Class I recall classification, in particular, demonstrates that the FDA determined there was a reasonable probability of serious health consequences or death — a finding that directly supports claims of product defect.

What You Should Do Now

If you or a loved one underwent an endoscopic procedure and developed a serious infection afterward, the FDA's regulatory actions against Olympus may directly support your legal claim. The connection between contaminated scopes and patient infections is well-documented, and our team — which includes a medical-legal expert with both an M.D. and J.D. — has the expertise to evaluate your case and determine whether an Olympus endoscope may have caused your injury.

Review infection symptoms Request a free case review

The Bigger Picture: A Pattern of Known Risk

When viewed together, the FDA's actions against Olympus endoscopes tell a clear story. In 2015, the FDA identified the problem. In 2016, the FDA ordered Olympus to study the problem. In 2019, the FDA recommended alternatives. In 2025, the FDA issued a Class I recall and blocked 58 models at the border. At every stage, the evidence grew stronger, and at every stage, patients continued to be exposed to contaminated devices. The question is not whether Olympus knew about the risks — the FDA's regulatory record makes it clear they did. The question is why patients were not protected sooner, and who should be held accountable for the infections and deaths that resulted.

The Alvarez Law Firm is committed to holding Olympus and other responsible parties accountable for the harm caused by contaminated endoscopes. Our team combines the trial expertise of Board Certified civil trial lawyers with the medical knowledge of Herb Borroto, M.D., J.D., who brings a rare dual perspective as both a physician and an attorney. This combination allows us to understand the medical evidence, identify failures in device design and reprocessing, and build the strongest possible cases for our clients. If you believe you or a loved one was harmed by a contaminated Olympus endoscope, we encourage you to contact us for a free, confidential case review.

Take Action Today

The FDA Has Taken Action.
Now It's Your Turn.

The FDA has documented the risks. Class I recalls have been issued. Import alerts have blocked 58 Olympus endoscope models from entering the country. If you or a loved one developed a serious infection after an endoscopic procedure, these regulatory findings may support your legal claim. Our team is ready to review your case at no cost and with no obligation. We only get paid if we win.

Free Case Review (305) 444-7675

No fee unless we win. Completely confidential. Nationwide representation.

(305) 444-7675 Free Case Review